Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—amoxicillin, metronidazole, and doxycycline. Each component has a distinct mechanism of action: - **Amoxicillin** is a penicillin-type beta-lactam antibiotic that inhibits bacterial cell wall synthesis. - **Metronidazole** is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa by disrupting DNA synthesis. - **Doxycycline** is a tetracycline-class antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit. This combination does not have an established brand or code name as a fixed-dose product but may be used off-label in clinical practice for complex or refractory infections where broad-spectrum coverage—including both aerobic and anaerobic bacteria—is required. It has been studied in the context of periodontal disease (as adjunctive therapy) and considered for use against persistent forms of *Borrelia burgdorferi* (Lyme disease), though not as an approved fixed combination[1][2]. Each drug individually is widely used for various bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + metronidazole + doxycycline.